SLDB — Solid Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $519.16m
- $397.22m
- 29
- 14
- 98
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 83.5 | 155 | 208 | 214 | 124 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | 0.11 | 0 | — |
Prepaid Expenses | |||||
Total Current Assets | 86.3 | 159 | 223 | 220 | 130 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.6 | 11.7 | 7.6 | 38.6 | 33.2 |
Other Long Term Assets | |||||
Total Assets | 103 | 171 | 232 | 260 | 165 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18.3 | 24.5 | 23.6 | 22.5 | 14.5 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 23.4 | 39.1 | 24.2 | 48.6 | 38.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 80 | 132 | 208 | 212 | 126 |
Total Liabilities & Shareholders' Equity | 103 | 171 | 232 | 260 | 165 |
Total Common Shares Outstanding |